Immatics (IMTX) Income from Continuing Operations (2019 - 2026)
Immatics (IMTX) posted Income from Continuing Operations of 41242061.73 for Q4 2025, up 30.55% sequentially from 59386829.59 in Q3 2025, and down 184.29% YoY from 48927777.59 in Q4 2024.
Powered by 
Analysis
Immatics (IMTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Immatics has reported Income from Continuing Operations for 7 years, with the latest figure at 41242061.73 in Q4 2025.
- Quarterly Income from Continuing Operations fell 184.29% year-over-year to 41242061.73 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 226540175.34 (down 875.72% YoY) and the FY2025 annual result came in at 226442407.73, down 861.51% from the prior year.
- Income from Continuing Operations improved to 41242061.73 in Q4 2025 per IMTX's latest filing, from 59386829.59 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 96141693.63 in Q1 2022 and troughed at 81897283.43 in Q2 2025.
- A 5-year average of 17355436.62 and a median of 23996855.1 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations soared 449.38% in 2022, then plunged 9127.64% in 2025.
- Over 5 years, Income from Continuing Operations stood at 19203840.36 in 2021, then surged by 111.78% to 2261888.41 in 2022, then tumbled by 1343.81% to 28133676.74 in 2023, then jumped by 273.91% to 48927777.59 in 2024, then plunged by 184.29% to 41242061.73 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 41242061.73, 59386829.59, and 81897283.43 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -73.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -73.28 Mn |
| Mar 31, 2026 | -67.56 Mn |
| Dec 31, 2025 | -41.24 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -81.90 Mn |
| Mar 31, 2025 | -44.01 Mn |
| Dec 31, 2024 | 48.93 Mn |
| Sep 30, 2024 | 657,833.48 |
| Jun 30, 2024 | -19.07 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |